{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:02:45Z","timestamp":1789225365948,"version":"build-2803163510"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) -targeting agents, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies could play a role in PCL treatment. However, PCL patients were excluded from recent pivotal clinical trials testing those agents and only some case reports have been published. We present here the clinical course of a patient with relapsed\/refractory (R\/R) primary (p) PCL who was treated with anti-BCMA and anti-GPRC5D bispecific antibodies at our center.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1495233","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:12:23Z","timestamp":1732846343000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-BCMA and GPRC5D bispecific antibodies in relapsed\/refractory primary plasma cell leukemia: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Chiara","family":"Bernardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Beauverd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien An","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Maulini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mappoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Simonetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cairoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger W.","family":"Auner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Samii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Ramon Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez De Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02114","article-title":"How we manage newly diagnosed multiple myeloma with circulating tumor cells","volume":"41","author":"Van De Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-139559","article-title":"Efficacy of daratumumab (Dara)-based regimens for the treatment of plasma cell leukemia (PCL)","volume":"136","author":"Parrondo","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v11.3","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901266","article-title":"Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125120","article-title":"Treatment of primary plasma cell leukemia with carfilzomib and lenalidomide-based therapy: results of the first interim analysis of the phase 2 EMN12\/HOVON129 study","volume":"134","author":"Van De Donk","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05027-y","article-title":"VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed\/refractory multiple myeloma: a single-center experience","volume":"102","author":"Ghandili","year":"2023","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:12:25Z","timestamp":1732846345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2024.1495233"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1495233","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"article-number":"1495233"}}